Jacqueline A Pongracic1, Rebecca Z Krouse2, Denise C Babineau2, Edward M Zoratti3, Robyn T Cohen4, Robert A Wood5, Gurjit K Khurana Hershey6, Carolyn M Kercsmar6, Rebecca S Gruchalla7, Meyer Kattan8, Stephen J Teach9, Christine C Johnson3, Leonard B Bacharier10, James E Gern11, Steven M Sigelman12, Peter J Gergen12, Alkis Togias12, Cynthia M Visness2, William W Busse11, Andrew H Liu13. 1. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill. Electronic address: jpongracic@luriechildrens.org. 2. Rho Federal Systems Division, Chapel Hill, NC. 3. Henry Ford Health System, Detroit, Mich. 4. Boston University School of Medicine, Boston, Mass. 5. Johns Hopkins University School of Medicine, Baltimore, Md. 6. Cincinnati Children's Hospital, Cincinnati, Ohio. 7. University of Texas Southwestern Medical Center, Dallas, Tex. 8. College of Physicians and Surgeons, Columbia University, New York, NY. 9. Children's National Health System and the George Washington University School of Medicine and Health Sciences, Washington, DC. 10. St Louis Children's Hospital, St Louis, Mo. 11. University of Wisconsin School of Medicine and Public Health, Madison, Wis. 12. National Institute of Allergy and Infectious Diseases, Bethesda, Md. 13. National Jewish Health, Denver, and Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo.
Abstract
BACKGROUND: Treatment levels required to control asthma vary greatly across a population with asthma. The factors that contribute to variability in treatment requirements of inner-city children have not been fully elucidated. OBJECTIVE: We sought to identify the clinical characteristics that distinguish difficult-to-control asthma from easy-to-control asthma. METHODS: Asthmatic children aged 6 to 17 years underwent baseline assessment and bimonthly guideline-based management visits over 1 year. Difficult-to-control and easy-to-control asthma were defined as daily therapy with 500 μg of fluticasone or greater with or without a long-acting β-agonist versus 100 μg or less assigned on at least 4 visits. Forty-four baseline variables were used to compare the 2 groups by using univariate analyses and to identify the most relevant features of difficult-to-control asthma by using a variable selection algorithm. Nonlinear seasonal variation in longitudinal measures (symptoms, pulmonary physiology, and exacerbations) was examined by using generalized additive mixed-effects models. RESULTS: Among 619 recruited participants, 40.9% had difficult-to-control asthma, 37.5% had easy-to-control asthma, and 21.6% fell into neither group. At baseline, FEV1 bronchodilator responsiveness was the most important characteristic distinguishing difficult-to-control asthma from easy-to-control asthma. Markers of rhinitis severity and atopy were among the other major discriminating features. Over time, difficult-to-control asthma was characterized by high exacerbation rates, particularly in spring and fall; greater daytime and nighttime symptoms, especially in fall and winter; and compromised pulmonary physiology despite ongoing high-dose controller therapy. CONCLUSIONS: Despite good adherence, difficult-to-control asthma showed little improvement in symptoms, exacerbations, or pulmonary physiology over the year. In addition to pulmonary physiology measures, rhinitis severity and atopy were associated with high-dose asthma controller therapy requirement.
BACKGROUND: Treatment levels required to control asthma vary greatly across a population with asthma. The factors that contribute to variability in treatment requirements of inner-city children have not been fully elucidated. OBJECTIVE: We sought to identify the clinical characteristics that distinguish difficult-to-control asthma from easy-to-control asthma. METHODS: Asthmatic children aged 6 to 17 years underwent baseline assessment and bimonthly guideline-based management visits over 1 year. Difficult-to-control and easy-to-control asthma were defined as daily therapy with 500 μg of fluticasone or greater with or without a long-acting β-agonist versus 100 μg or less assigned on at least 4 visits. Forty-four baseline variables were used to compare the 2 groups by using univariate analyses and to identify the most relevant features of difficult-to-control asthma by using a variable selection algorithm. Nonlinear seasonal variation in longitudinal measures (symptoms, pulmonary physiology, and exacerbations) was examined by using generalized additive mixed-effects models. RESULTS: Among 619 recruited participants, 40.9% had difficult-to-control asthma, 37.5% had easy-to-control asthma, and 21.6% fell into neither group. At baseline, FEV1 bronchodilator responsiveness was the most important characteristic distinguishing difficult-to-control asthma from easy-to-control asthma. Markers of rhinitis severity and atopy were among the other major discriminating features. Over time, difficult-to-control asthma was characterized by high exacerbation rates, particularly in spring and fall; greater daytime and nighttime symptoms, especially in fall and winter; and compromised pulmonary physiology despite ongoing high-dose controller therapy. CONCLUSIONS: Despite good adherence, difficult-to-control asthma showed little improvement in symptoms, exacerbations, or pulmonary physiology over the year. In addition to pulmonary physiology measures, rhinitis severity and atopy were associated with high-dose asthma controller therapy requirement.
Authors: H Eigen; H Bieler; D Grant; K Christoph; D Terrill; D K Heilman; W T Ambrosius; R S Tepper Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405
Authors: Robert S Tepper; Robert S Wise; Ronina Covar; Charles G Irvin; Carolyn M Kercsmar; Monica Kraft; Mark C Liu; George T O'Connor; Stephen P Peters; Ronald Sorkness; Alkis Togias Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Elizabeth C Matsui; Peyton A Eggleston; Timothy J Buckley; Jerry A Krishnan; Patrick N Breysse; Cynthia S Rand; Gregory B Diette Journal: Ann Allergy Asthma Immunol Date: 2006-10 Impact factor: 6.347
Authors: Meyer Kattan; Rajesh Kumar; Gordon R Bloomberg; Herman E Mitchell; Agustin Calatroni; Peter J Gergen; Carolyn M Kercsmar; Cynthia M Visness; Elizabeth C Matsui; Suzanne F Steinbach; Stanley J Szefler; Christine A Sorkness; Wayne J Morgan; Stephen J Teach; Vanthaya N Gan Journal: J Allergy Clin Immunol Date: 2010-03 Impact factor: 10.793
Authors: Robert C Strunk; Ryan Colvin; Leonard B Bacharier; Anne Fuhlbrigge; Erick Forno; Ana Maria Arbelaez; Kelan G Tantisira Journal: J Allergy Clin Immunol Pract Date: 2015-07-09
Authors: Päivi M Salo; Samuel J Arbes; Renee Jaramillo; Agustin Calatroni; Charles H Weir; Michelle L Sever; Jane A Hoppin; Kathryn M Rose; Andrew H Liu; Peter J Gergen; Herman E Mitchell; Darryl C Zeldin Journal: J Allergy Clin Immunol Date: 2014-02-09 Impact factor: 10.793
Authors: William J Sheehan; Jonathan M Gaffin; David B Peden; Robert K Bush; Wanda Phipatanakul Journal: J Allergy Clin Immunol Date: 2017-12 Impact factor: 10.793
Authors: Alkis Togias; Peter J Gergen; Jack W Hu; Denise C Babineau; Robert A Wood; Robyn T Cohen; Melanie M Makhija; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Rebecca S Gruchalla; Andrew H Liu; Emily Wang; Haejin Kim; Carin I Lamm; Leonard B Bacharier; Dinesh Pillai; Steve M Sigelman; James E Gern; William W Busse Journal: J Allergy Clin Immunol Date: 2018-09-11 Impact factor: 10.793
Authors: Anna Pomés; Geoffrey A Mueller; Thomas A Randall; Martin D Chapman; L Karla Arruda Journal: Curr Allergy Asthma Rep Date: 2017-04 Impact factor: 4.806
Authors: Daniel J Jackson; Leonard B Bacharier; Agustin Calatroni; Michelle A Gill; Jack Hu; Andrew H Liu; Lisa M Wheatley; James E Gern; Rebecca S Gruchalla; Gurjit K Khurana Hershey; Meyer Kattan; Carolyn M Kercsmar; Haejin Kim; George T O'Connor; Shilpa Patel; Jacqueline A Pongracic; Robert A Wood; William W Busse Journal: J Allergy Clin Immunol Date: 2020-01-28 Impact factor: 10.793
Authors: Ronald L Sorkness; Edward M Zoratti; Meyer Kattan; Peter J Gergen; Michael D Evans; Cynthia M Visness; Michelle Gill; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Andrew H Liu; George T O'Connor; Jacqueline A Pongracic; Dinesh Pillai; Christine A Sorkness; Alkis Togias; Robert A Wood; William W Busse Journal: J Allergy Clin Immunol Date: 2017-11-14 Impact factor: 10.793
Authors: Rebecca Z Krouse; Christine A Sorkness; Jeremy J Wildfire; Agustin Calatroni; Rebecca Gruchalla; Gurjit K Khurana Hershey; Meyer Kattan; Andrew H Liu; Melanie Makhija; Stephen J Teach; Joseph B West; Robert A Wood; Edward M Zoratti; Peter J Gergen Journal: J Allergy Clin Immunol Date: 2016-10-12 Impact factor: 10.793
Authors: Alice M Cottee; Leigh M Seccombe; Cindy Thamrin; Gregory G King; Matthew J Peters; Claude S Farah Journal: Chest Date: 2020-01-23 Impact factor: 9.410
Authors: Elena Goleva; Denise C Babineau; Michelle A Gill; Leisa P Jackson; Baomei Shao; Zheng Hu; Andrew H Liu; Cynthia M Visness; Christine A Sorkness; Donald Y M Leung; Alkis Togias; William W Busse Journal: J Allergy Clin Immunol Date: 2018-07-27 Impact factor: 10.793